Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C21H31NO2.ClH |
| Molecular Weight | 365.937 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCCOC(=O)C1(C[C@@H]2CC[C@H]1C2)C3=CC=CC=C3
InChI
InChIKey=ODVPRPWQGNOPAY-PWITVKHSSA-N
InChI=1S/C21H31NO2.ClH/c1-3-22(4-2)13-8-14-24-20(23)21(18-9-6-5-7-10-18)16-17-11-12-19(21)15-17;/h5-7,9-10,17,19H,3-4,8,11-16H2,1-2H3;1H/t17-,19+,21?;/m1./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H31NO2 |
| Molecular Weight | 329.4763 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bornaptine is a synthetic anticholinergic drug. The compound is a nonselective M1 and M4 antagonist and was shown to inhibit the negative inotropic response to carbachol in the isolated left atrium of the rat with pA2 of 7.27. Bornaprine is used for the treatment of symptoms of Parkinson's disease. A clinical trial showed the superiority of Bornaprine over placebo in reducing parkinsonian tremor. Bornaptine demonstrated positive results in localized hyperhidrosis.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:39:56 GMT 2025
by
admin
on
Mon Mar 31 18:39:56 GMT 2025
|
| Record UNII |
R99RGW1B2Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70949699
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
248-100-5
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
235767
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
118984396
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
26908-91-8
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
100000091913
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
C006088
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
R99RGW1B2Q
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY | |||
|
SUB00856MIG
Created by
admin on Mon Mar 31 18:39:56 GMT 2025 , Edited by admin on Mon Mar 31 18:39:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |